ArriVent BioPharma, Inc.

XNASHealth care

Last traded price · USD

$13.36

−0.96%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:45 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $13.49
Volume: 445
Day's high: —
Day's low: —

In brief

ArriVent BioPharma, Inc. is a health care company listed on Nasdaq, valued at about $659M.
Its shares closed at $13.49 on 4 Nov 2026, down 27.9% over the past year.
From India you can buy AVBP in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy ArriVent BioPharma, Inc. (AVBP) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole AVBP share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade AVBP options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −10.6% (SPY −1.6%, XLV +13.5%). 3 months: −55.9% (SPY −0.4%, XLV +15.5%). 1 year: −27.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AVBP, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $13.49 was 43.3% below its 50-day average ($23.78) and 49.7% below its 200-day average ($26.83). It has closed below the 200-day for 22 sessions, since 6 Oct 2026. The 50-day average crossed below the 200-day on 19 Oct 2026, 12 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
18.8% above its 52-week low
Closed at $13.49 on 4 Nov 2026: 62.3% below the 52-week high of $35.83 (26 Jun 2026) and 18.8% above the low of $11.36 (6 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 13.8% of shares outstanding
6.8M shares were sold short at the 15 Oct 2026 settlement, 13.8% of the 49.3M shares outstanding; covering them would take 2.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−10.6%

6 months−54.5%

1 year−27.9%

5 years—

Newswire

About

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

Website

Notable moves

October 26, 2026
−26.86%
October 6, 2026
−46.98%
July 20, 2026
−14.97%

ArriVent BioPharma, Inc.

XNASHealth care

Last traded price · USD

$13.36

−0.96%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:45 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $13.49
Volume: 445
Day's high: —
Day's low: —

In brief

ArriVent BioPharma, Inc. is a health care company listed on Nasdaq, valued at about $659M.
Its shares closed at $13.49 on 4 Nov 2026, down 27.9% over the past year.
From India you can buy AVBP in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy ArriVent BioPharma, Inc. (AVBP) shares from India?

Do I need the price of a whole AVBP share to invest?

How much can I invest in US stocks in a year?

Can I trade AVBP options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −10.6% (SPY −1.6%, XLV +13.5%). 3 months: −55.9% (SPY −0.4%, XLV +15.5%). 1 year: −27.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AVBP, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $13.49 was 43.3% below its 50-day average ($23.78) and 49.7% below its 200-day average ($26.83). It has closed below the 200-day for 22 sessions, since 6 Oct 2026. The 50-day average crossed below the 200-day on 19 Oct 2026, 12 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
18.8% above its 52-week low
Closed at $13.49 on 4 Nov 2026: 62.3% below the 52-week high of $35.83 (26 Jun 2026) and 18.8% above the low of $11.36 (6 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 13.8% of shares outstanding
6.8M shares were sold short at the 15 Oct 2026 settlement, 13.8% of the 49.3M shares outstanding; covering them would take 2.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−10.6%

6 months−54.5%

1 year−27.9%

5 years—

Newswire

About

Website

Notable moves

October 26, 2026
−26.86%
October 6, 2026
−46.98%
July 20, 2026
−14.97%

ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

18.8% above its 52-week low

Short interest at 13.8% of shares outstanding

ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

18.8% above its 52-week low

Short interest at 13.8% of shares outstanding